Cost effectiveness in new technologies  by Amendola, Beatriz
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S9–S11
Available online at www.sciencedirect.com
journa l homepage: ht tp : / /www.e lsev ier .com/ locate / rpor
Management workshop
Cost effectiveness in new technologies
Beatriz Amendola
Innovative Cancer Institute, United States
1. Introduction
For the past several decades it has become obvious that the
unconstrained cost of health care is not compatible with the
long-term economic viability of developed countries and even
less in developing countries. When the goal is to cure and
provide quality of care to the largest number of patients at
the lowest cost, the means to achieve this end needs to be
particularly reviewed in our ﬁeld. The measurement of qual-
ity is a relatively new science, which requires a large amount
of resources to develop and collect the necessary information.
Fully developed and tested quality measures are only avail-
able for some of the most common conditions or processes of
health care delivery. Basically, the concept of increasing qual-
ity in health care delivery is based on the premise of patient
outcomes as a function of cost.
Greater quality by this deﬁnition can be provided by
improving outcomes while holding costs the same, providing
similar outcomes at a reduced cost, or some combination of
better outcomes and reduced cost.
A number of methodologies have been developed to assess
the relative cost-effectiveness of different interventions in the
hope of making rationale choices based on the best evidence
available. However, the best management strategy frequently
depends on the perspective of the analysis, and for individ-
ual patients, does not take into account the emotional and
economic factors that complicate medical decision making.
Despite the intense interest in health care expenditures
in developed countries, far less information is available on
the economic considerations of medical care in third-world
countries.
Global oncology spending will reach $75Bn by 2015, rising
at a much slower rate than in the past ﬁve years, as existing
targeted therapies have already been widely adopted in most
developed markets, some major products will be exposed to
generic competition, and new products, with the potential
to extend lives, will add treatment options in several major
tumors, but will not contribute to signiﬁcantly higher spend-
ing. Our specialty is no less than the oncology counterpart
regarding the rising cost of cancer care as technology to deliv-
ered targeted therapies becomes necessary and available.
Cost-effectiveness analysis can be used to help set priori-
ties for funding health care programs. For each intervention,
the costs and clinical outcomes associated with that strat-
egy must be compared with an alternate strategy for treating
the same patients. If an intervention results in improved
outcomes but also costs more, the incremental cost per incre-
mental unit of clinical outcome should be calculated.1
Steps for how to calculate cost:
1. The ﬁrst step is demonstration of efﬁcacy of the technique.
2. The second step involves assessment of effectiveness.
3. The third step assesses efﬁciency or cost effectiveness
which considers both the effectiveness of the health care
intervention aswell as the resources required to deliver the
intervention.
4. The fourth step considers the issue of availability of ser-
vices to locations accessible to patients who require them.
5. The ﬁfth, and often overriding step in a policy analysis
concerning the evaluation of a health care technology, con-
siders distribution, that is, an examination of who gains
and who loses by choosing to allocate resources to one
health care program instead of another.
Cost–utility was deﬁned as cost in dollars for a particular
therapy per unit clinical outcome, deﬁned as the median sur-
vival in quality-adjusted life-years (QALYs). For all sites it is
required for all treatments to be equivalent and provide long-
term efﬁcacy with similar toxicity, but lower cost.
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2. Cost of systemic chemotherapy
When comparing costs of radiotherapy and systemic
chemotherapy, it is like comparing night and day. Costs of
chemotherapy are in the billions in USA, as opposed to costs
of radiotherapy, which is a minimal fraction of that cost.
A recent article describes the magnitude of this problem:
“. . .provision of more aggressive care by physicians, the pro-
longation of the period of treatment and patient survival,
and . . . an aging population, are important drivers of the ris-
ing costs.” Regarding the cost value dissociation, in cancer
management many factors are involved including imaging,
radiotherapy, surgical procedures, etc.2
In a recent report from the IMS Institute for Healthcare
Informatics, in theUnitedStates oncologic drugs ledall classes
in drug spending in 2011, at $23.2 billion. Spending on tar-
geted agents grew by $1.1 billion, higher than the $0.8 billion
spending increase in 2010.3
Some medications have marginal beneﬁts that can be
measured in a few weeks (or days) of additional life, with
associated toxicities so high prices may not be justiﬁed by
the limited beneﬁts of these drugs. While the pharmaceuti-
cal companies have the capacity to decide the cost of these
drugs United States market, that favors the development of
minimally beneﬁcial drugs at very high costs to the insurance
companies and tax payers. An example of this exact situation
is “sipuleucel-T (Provenge),” an agent for metastatic prostate
cancer, which only shows amedian survival of 4months.4 The
price tag of Provenge is $93,000 for the required three doses.
If Radiation Oncologists use an alternative such as Samarium
153 single IV of radioisotope dose for extensivemetastatic dis-
ease the price for this procedure is approximately $5000.00
with a 6 month pain control period.5
In the USA’s current healthcare market, most patients are
not responsible for payments. These funds originate from
the taxes charged to the citizens that usually cover about
70–80% of the medical costs in patients older than 65 years.6
In younger patients, private insurances cover part of this cost.
If the patient have has no health insurance, they are forced to
pay “out-of-pocket,” or not receive treatment at all.
With increasing costs, cost-sharing arrangements, also
referred to as copayments, as a method to decrease usage has
become very common and patients are responsible for paying
a part of the treatment cost. The insurance plans with high
deductibles are very common now-a-days.7
A study fromBernard et al. shows that cancer patients have
a greater ﬁnancial burden than patients with other chronic
illnesses; 13% of the cancer patients spend at least a 20% of
their income on healthcare costs and insurance.8
Modern technologies in radiation therapy care show sim-
ilarities in chemotherapy drugs’ high cost regarding the
reimbursement and approval by insurance companies. Unfor-
tunately, the approval of these procedures lies in the hands
of uninformed or misinformed consultants whom approve or
deny these modalities of therapy based on capricious intent.
Radiation therapy using modern technology result in high
cure rate at both a far less cost and toxicity that some of the
drugs appearing up in the market, which demonstrate mini-
mal advantages sometimes such as survival of few weeks at
impressively high cost not only ﬁnancial, but also physical
health.
3. Technological advances: improving
technology can decrease cost
Major technological progress certainly comes at a higher
cost, and there are many concerns regarding the value of
that progress. On the other hand, the newer equipment and
resources costs associated with cutting-edge radiation oncol-
ogy technologies can be partly mitigated by shorter treatment
courses. Better tumor control, less toxicity, and fewer treat-
ment courses decrease the indirect costs of cancer care,
including lost time and economic productivity secondary to
treatment-related and cancer-related illness and death.
4. Some speciﬁc examples of how new
technologies in radiation therapy is cost
effective
4.1. Radiation therapy techniques: SBRT
Because SBRT is used in more clinical situations, it is imper-
ative to assess its cost-effectiveness as well as its efﬁcacy.
SBRT employing image guidance, high-precision dose deliv-
ery, more accurate target deﬁnition with better anatomical
and biological imaging, and the possibility of dose veriﬁcation
during treatment via dose-adaptive radiation therapy permits
a higher probability of tumor control.
4.2. Cost effectiveness in APBI vs. WBRT
Multiple regimens using EBRT, 3D, IMRT vs. brachytherapy,
HDR multilumen, single lumen and/or interstitial brachyther-
apywere compared and demonstrated that APBI was themost
cost effective for treating early breast cancer.9
4.3. Prostate cancer
The incremental cost of using daily IGRT when using IMRT is
moderate and it is reasonable when is to be used when pre-
cision and high doses of radiation are needed. This cost can
be overcomewith the use of hypofractionation using 25 rather
than the commonly used 45 fractions.10,11
If we invest in new technology our gain can be seen in the
following example of capital equipment investment in a
radiation oncology department: the most costly piece of
equipment is the linear accelerator. If we start with a capi-
tal equipment investment of $4.1 million, we can estimate
$4.4million in gross annual revenue assuming 289 patients
completing a course of radiation therapy, which will give
us a $2.6 million in year 1 net income, which assumes
operational expenses of $1.8 million. For the following year
we have an estimated $356 thousand in incremental net
income, which assumes an increase of 63 new patients
than in the previous year. Information – Courtesy of Varian
Medical Systems
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S9–S11 S11
r e f e r enc e s
1. Detsky AS, Naglie IG. A clinician’s guide to cost-effectiveness
analysis. Ann Intern Med 1990;113(2):147–54.
2. De Souza JA. The cost of cancer care: there is more than one
elephant in the room. Oncology 2012;26(10):926.
3. IMS Institute for Healthcare Informatics: The use of medicine in the
United States: review of 2011. April 2012. Available from:
http://www.imshealth.com/ims/Global/Content/Insights/
IMS Institute for Healthcare Informatics/IHII Medicines in
U.S Report 2011.pdf (accessed 20.09.12).
4. Small EJ, Schellhammer PF, Higano CS, et al.
Placebo-controlled phase III trial of immunologic therapy
with sipuleucel-T (APC8015) in patients with metastatic,
asymptomatic hormone refractory prostate cancer. J Clin
Oncol 2006;24:3089–94.
5. Sartora O, Reidb RH, Hoskinc PJ, et al.
Samarium-153-Lexidronam complex for treatment of painful
bone metastases in hormone-refractory prostate cancer.
Urology 2004;63(5):940–5.
6. Willey VJ, Pollack MF, Lawless GD. Oncology health care and
patient out-of-pocket cost trends in a commercially insured
population. J Clin Oncol 2008;26(May (Suppl.)) [abstr 6503].
7. America’s Health Insurance Plans (AHIP) Center for Policy
and Research. 2012 HSA census. Available from:
http://www.ahip.org/HSA2012 [accessed 20.09.12].
8. Bernard DSM, Farr SL, Fang Z. National estimates of
out-of-pocket health care expenditure burdens among
nonelderly adults with cancer: 2001 to 2008. J Clin Oncol
2011;29:2821–6.
9. Shah C, Lanni T, Wilkinson JB, et al. Cost-effectiveness of 3
dimensional conformal radiotherapy and applicator-based
brachytherapy in the delivery of accelerated partial breast
irradiation. Am J Clin Oncol 2012.
10. Perrier L, Morelle M, Pommier P, et al. Cost of prostate image
guided radiation therapy: results of a randomized trial.
Radiother Oncol; in press.
11. Cooperberg MR, Ramakrishna NR, Duff SB, et al. Primary
treatments for clinically localized prostate cancer: a
comprehensive lifetime cost–utility analysis. BJU Int 2012,
http://dx.doi.org/10.1111/J.1464-410X.2012.11597.X.
